DYRK1A and triple-negative breast carcinoma: Our study, importantly, also highlights a new therapeutic strategy, targeting DYRK1A, with promising results to sensitize the tumors to G1/S phase-specific chemotherapy treatment in both triple negative breast cancer and colon cancer.